Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 18/20 | 0.54 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | MMEL1 | Q495T6 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11969353 | 1.00 | MME (0.54) | MMEACEMMEL1 | |
| SCHEMBL13740650 | 1.00 | MME (0.54) | MMEACEMMEL1 | |
| SCHEMBL11969623 | 0.91 | MME (0.59) | MMEACEMMEL1 | |
| SCHEMBL11969630 | 0.91 | MME (0.59) | MMEACEMMEL1 | |
| SCHEMBL11969536 | 0.89 | MME (0.47) | MMEACEMMEL1 | |
| SCHEMBL11970038 | 0.88 | MME (0.69) | MMEACE | |
| SCHEMBL12480836 | 0.88 | MME (0.69) | MMEACE | |
| SCHEMBL19875312 | 0.88 | MME (0.69) | MMEACE | |
| SCHEMBL11969569 | 0.88 | MME (0.69) | MMEACE | |
| SCHEMBL12480732 | 0.88 | MME (0.69) | MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9725448-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | claimed |
| US-20170066764-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-09 | — | — | US | claimed |
| US-20180051023-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-9725448-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170066764-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-09 | — | — | US | disclosed |
| US-9487514-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2675792-B1 | SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150133658-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-05-14 | — | — | US | disclosed |
| US-8846913-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130245260-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8449890-B2 | Neprilysin inhibitors | THERAVANCE, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120213807-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133658-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | MME 1/4885ACE 5/4885MMEL1 322/4885 |
| US-20120213807-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | MME 1/4885ACE 5/4885MMEL1 322/4885 |
| US-20170066764-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | MME 1/4885ACE 5/4885MMEL1 322/4885 |
| US-20130245260-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | MME 1/4885ACE 5/4885MMEL1 322/4885 |
| US-20180051023-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | MME 1/4885ACE 5/4885MMEL1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.